share_log

Hoth Therapeutics Announces FDA Acceptance Of IND Application For HT-001 For Treatment Of Cancer Disorders Associated With Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics Announces FDA Acceptance Of IND Application For HT-001 For Treatment Of Cancer Disorders Associated With Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

霍斯治療宣布 FDA 接受 HT-001 用於治療與表皮生長因子受體（EGFR）抑製劑治療相關的癌症疾病的 IND 申請
Benzinga Real-time News ·  2022/12/29 08:47

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

以患者為中心的生物製藥公司 Hoth Theraptics Inc. (NASDAQ: HOTH) 今天宣布，美國食品藥物管理局 (FDA) 已接受一項研究性新藥 (IND) 申請，用於治療與表皮生長因子受體 (EGFR) 抑制劑治療相關的皮疹和皮膚疾病。HT-001EGFR 抑制劑是治療非小細胞肺癌（NSCLC）、胰臟癌、結直腸癌、頭頸鱗狀細胞癌和乳癌的重要治療藥物。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論